Latest News

Newly published KINECT-PRO data showed that valbenazine boosted quality of life and function while reducing movement severity, with remission for many patients with tardive dyskinesia by 24 weeks.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 4, 2026.

Olfactory dysfunction, dysautonomia, mood disturbance, and motor deficits disproportionate to dopaminergic denervation may serve as markers of amyloid-β positivity in newly diagnosed Parkinson disease.

Findings from a new study showed that over 90% of counties in the United States lacked a UCNS-certified headache specialist, with access lowest in socioeconomically disadvantaged and rural areas.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Aaron Zelikovich, MD. [LISTEN TIME: 18 minutes]

Catch up on any of the neurology headlines you may have missed in August 2026, compiled into 1 place by the NeurologyLive® team.

FDA approved Zanvastro (zilganersen), the first therapy to directly target the GFAP protein buildup that drives Alexander disease, based on a phase 3 trial showing improved walking speed and motor function versus untreated controls.

A recent study suggests that cumulative genetic variation associated with lymphocyte counts may help identify patients living with multiple sclerosis at increased risk of dimethyl fumarate-associated lymphopenia.

Newly published longitudinal fMRI data revealed that presymptom Huntington gene carriers had striatal network shifts up to 20 years early, potentially sharpening targets for studies in the future.

A recently published multiple sclerosis study suggests disease-modifying therapy use may be associated with higher rates of human papillomavirus positivity, cervical abnormalities, and other gynecologic complications.

Thayne Munce, PhD, discusses the challenges and unanswered questions shaping CTE research, as well as the implications of findings from former NFL players for athletes competing today.

uniQure submitted a BLA to FDA and an MAA to the UK's MHRA for ifezuntirgene inilparvovec, based on 3-year phase 1/2 data showing slowed Huntington disease progression.

The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.